NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled
NCT00831844 2015-03-30Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI)Phase 2 Completed116 enrolled 8 charts